Maria Reig
BCLC group. Liver Unit. Hospital Clinic. Ciberehd
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Maria Reig as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:53 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04316182 · Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)Fundacion Clinic per a la Recerca Biomédica · completed · Hepatocellular Carcinoma · principal investigator
- Ph1/Ph2NCT04170556 · Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)Fundacion Clinic per a la Recerca Biomédica · completed · Hepatocellular Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:53 UTC. The ranking covers the 200 most relevant of 16 PubMed records, and a shared surname and initials can bring in a namesake. All 16 on PubMed
- Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.J Hepatol · 2016591 citationsRCR 21.8
- Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.Ann Oncol · 2024349 citationsRCR 43.4
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.Lancet Oncol · 2018302 citationsRCR 10.4
- Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.Eur J Cancer · 2013214 citationsRCR 5.9
- Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.J Hepatol · 2025151 citationsRCR 34.4
- 121 citationsRCR 24.1
- Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study.J Immunother Cancer · 202278 citationsRCR 5.6
- 43 citationsRCR 9.9
- 26 citationsRCR 13.0
- 24 citationsRCR 0.8